ELI LILLY AND COMPANY Other Receivables, Net, Current
ELI LILLY AND COMPANY (LLY) had Other Receivables, Net, Current of $3.39 billion as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes
us-gaap:OtherReceivablesNetCurrent · last filed 2026-08-05
- 2026-06-30: Other Receivables, Net, Current $3.39B.
- 2026-03-31: Other Receivables, Net, Current $2.75B.
- 2025-12-31: Other Receivables, Net, Current $2.40B.
- 2025-09-30: Other Receivables, Net, Current $3.35B.
| Period end | Other Receivables, Net, Current | Other Receivables, Net, Current as first filed |
|---|---|---|
| 2026-06-30 | $3.39B 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $2.75B 10-Q · filed 2026-04-30 | |
| 2025-12-31 | $2.40B 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $3.35B 10-Q · filed 2025-10-30 | |
| 2025-06-30 | $3.04B 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $1.97B 10-Q · filed 2025-05-01 | |
| 2024-12-31 | $2.27B 10-K · filed 2026-02-12 | $2.27B 10-K · filed 2025-02-19 |
| 2024-09-30 | $1.76B 10-Q · filed 2024-10-30 | |
| 2024-06-30 | $2.05B 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $2.13B 10-Q · filed 2024-04-30 | |
| 2023-12-31 | $2.25B 10-K · filed 2025-02-19 | |
| 2023-09-30 | $2.20B 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $1.66B 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $1.50B 10-Q · filed 2023-04-27 | |
| 2022-12-31 | $1.66B 10-K · filed 2024-02-21 | |
| 2022-09-30 | $1.61B 10-Q · filed 2022-11-01 | |
| 2022-06-30 | $1.31B 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $1.48B 10-Q · filed 2022-04-29 | |
| 2021-12-31 | $1.45B 10-Q · filed 2022-11-01 | |
| 2021-09-30 | $1.11B 10-Q · filed 2021-10-27 | |
| 2021-06-30 | $1.07B 10-Q · filed 2021-08-03 | |
| 2021-03-31 | $1.07B 10-Q · filed 2021-04-30 | |
| 2020-12-31 | $1.05B 10-Q · filed 2021-10-27 | |
| 2020-09-30 | $958.10M 10-Q · filed 2020-10-28 | |
| 2020-06-30 | $946.70M 10-Q · filed 2020-07-31 | |
| 2020-03-31 | $1.25B 10-Q · filed 2020-05-01 | |
| 2019-12-31 | $994.20M 10-Q · filed 2020-10-28 | |
| 2019-09-30 | $1.10B 10-Q · filed 2019-10-25 | |
| 2019-06-30 | $977.50M 10-Q · filed 2019-08-02 | |
| 2019-03-31 | $977.50M 10-Q · filed 2019-05-02 | |
| 2018-12-31 | $1.18B 10-Q · filed 2019-10-25 | |
| 2018-09-30 | $793.20M 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $756.10M 10-Q · filed 2018-07-25 | |
| 2018-03-31 | $775.60M 10-Q · filed 2018-04-27 | |
| 2017-12-31 | $715.90M 10-Q · filed 2018-11-06 | |
| 2017-09-30 | $613.20M 10-Q · filed 2017-10-27 | |
| 2017-06-30 | $606.20M 10-Q · filed 2017-07-28 | |
| 2017-03-31 | $596.70M 10-Q · filed 2017-05-01 | |
| 2016-12-31 | $736.90M 10-Q · filed 2017-10-27 | |
| 2016-09-30 | $672.90M 10-Q · filed 2016-10-28 | |
| 2016-06-30 | $545.20M 10-Q · filed 2016-07-28 | |
| 2016-03-31 | $564.80M 10-Q · filed 2016-04-29 | |
| 2015-12-31 | $558.60M 10-Q · filed 2016-10-28 | |
| 2015-09-30 | $665.80M 10-Q · filed 2015-10-30 | |
| 2015-06-30 | $747.80M 10-Q · filed 2015-07-30 | |
| 2015-03-31 | $683.20M 10-Q · filed 2015-04-30 | |
| 2014-12-31 | $566.70M 10-Q · filed 2015-10-30 | |
| 2014-09-30 | $581.10M 10-Q · filed 2014-10-29 | |
| 2014-06-30 | $566.20M 10-Q · filed 2014-07-28 | |
| 2014-03-31 | $743.20M 10-Q · filed 2014-04-28 | |
| 2013-12-31 | $588.40M 10-Q · filed 2014-10-29 | |
| 2013-09-30 | $550.40M 10-Q · filed 2013-10-30 | |
| 2013-06-30 | $634.90M 10-Q · filed 2013-07-26 | |
| 2013-03-31 | $589.40M 10-Q · filed 2013-04-26 | |
| 2012-12-31 | $552.00M 10-Q · filed 2013-10-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |